CINV by MEC in clinical practice and rescue of it by NK1RA

CINV by MEC in clinical practice and rescue of it by NK1RA - CINV by MEC and NK1RA

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008430

Enrollment

Registered

2012-07-14

Start date

2012-07-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Oral aprepitant

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: MEC regimen for 1st cycle of line chomotherapy for lung cancer

Exclusion criteria

Exclusion criteria: Unable to intake aprepitant orally

Design outcomes

Primary

Measure	Time frame
Frequency of CINV	—

Secondary

Measure	Time frame
Toxicity and efficacy	—

Countries

Japan

Contacts

Public ContactFumio Imamura

Osaka Medical Center for Cancer and Cardiovascular Diseases Dept of Thoracic Oncology

imamura-fu@mc.pref.osaka.jp6-6972-1181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026